DRREDDY:NSE
瑞迪制药
₹1,240.00
arrow_upward
+0.86%(+10.60) 1 天
10月13日, GMT+5:30 15:30:00 · INR
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 DRREDDY 生成关键数据洞见…
开盘价
₹1,230.90
最高价
₹1,250.70
最低价
₹1,223.30
市值
1.03万亿
平均成交量
181.85万
成交量
241.78万
股息
0.65%
季度股息
₹2.00
除息日
2026年7月10日
市盈率
32.07
52 周最高价
₹1,414.90
52 周最低价
₹1,101.00
每股收益
₹38.67
流通股数
1.66亿
员工人数
3万
开盘价
₹1,230.90
最高价
₹1,250.70
最低价
₹1,223.30
市值
1.03万亿
平均成交量
181.85万
成交量
241.78万
股息
0.65%
季度股息
₹2.00
除息日
2026年7月10日
市盈率
32.07
52 周最高价
₹1,414.90
52 周最低价
₹1,101.00
每股收益
₹38.67
流通股数
1.66亿
员工人数
3万
新闻报道
来自网络来源和新闻合作伙伴
www.marketscreener.com
·
20小时前
Dr. Reddy's Laboratories Shares Rise After BNP Paribas Upgrade
资料
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
瑞迪制药简介